Dainippon Sumitomo Submits Lurasidone NDA, Preps For Marketing Scramble
This article was originally published in PharmAsia News
Executive Summary
WASHINGTON - Dainippon Sumitomo submitted an NDA to U.S. FDA for its atypical antipsychotic lurasidone for schizophrenia, and the company is hoping its newly acquired Sepracor sales force is up to the challenge in a crowded, but still fruitful, market